白细胞介素-11防治急性髓系白血病化疗后血小板减少的临床研究

  目的 观察重组人白细胞介素-11（rhIL-11）防治急性髓系白血病化疗后血小板减少的疗效及其不良反应。方法 采用自身对照研究的方法，对21例因化疗引起血小板减少（＜50×109／L）急性髓性白血病患者给予rhIL-11预防性治疗。第1周期单用化疗；第2周期化疗联合rhIL-11，即化疗结束后24 h开始用rhIL-11，25μg／kg，皮下注射，1次／d，连续用药14 d或连续2次检查血小板计数≥300×109／L停药。结果 共入选21例患者，2例因第1周期化疗后疾病进展，中止化疗而剔除，19例可评价疗效和毒性反应。对照周期：化疗后血小板最低值（31.9±9.2）×109／L，血小板＜50×109／L平均天数（8.9±3.3）d，输注同型异体血小板7例次。研究周期：化疗后血小板最低值（56.4±17.8）×109／L（P＜0.05），血小板＜50×109／L平均天数（4.6±2.9）d（P＜0.05），输注同型异体血小板3例次。结论rhIL-11可提高血小板最低值，缩短血小板减少持续时间、减少血小板输注量，耐受性良好。

Clinical study of rhIL-11 in prevention and treatment of chemotherapy-induced thrombocytopenia in patients with acute myelogenous leukemia

Objective The current study was designed to observe the efficacy and toxicity of recom－binant human interleukin-11 (rhIL-11) in prevention and treatment of chemotherapy-induced thrombocytope－nia in patients with acute myelogenous leukemia. Methods A total of 21 acute myelogenous leukemia pa－tients with chemotherapy-induced thrombocytopenia（<50×109/L） were involved into auto-control clinical study and every patient received 2 cycles of chemotherapy. Patients only received chemotherapy in the first cycle, in the second cycle, besides chemotherapy, rhIL-11 was administered subcutaneously (25 μg·kg-1·d-1), beginning 24 hours after completion of chemotherapy for 14 consecutive days or continuing until platelet count was ≥300×109/L. Results 21 patients were enrolled in this study. 2 of 21 cases excluded because of disease progression after the first circle of chemotherapy and withdrawal of rhIL-11. The other 19 were eligible for the evaluation of responses and toxicities. In the control cycle: the mean minimum platelet count was (31.9±9.2)×109/L. Mean days of the platelet count lower than 50×109/L were (8.9±3.3) days. Total 7 cases accepted infu－sion of platelet. Study cycle: the mean minimum platelet count was (56.4±17.8)×109/L（P < 0.05）. Mean days of the platelet count lower than 50×109/L were (4.6±2.9) days （P<0.05）. Total 3 cases accepted infusion of platelet. Conclusion rhIL-11 can reduce thrombocytopenia induced by chemotherapy and is a safe and ef－fective drug for treatment of thrombocytopenia.